Advertisement University of Houston releases Wellmune WGP study results - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

University of Houston releases Wellmune WGP study results

The randomized, double-blinded, placebo-controlled study of Wellmune WGP demostrated statistically significant higher concentrations of monocytes in subjects' blood compared with the blood samples while taking the placebo.

WGP is a natural functional food ingredient.

The study involved 60 athletes engaged in sustained aerobic exercise [31 women (age 22 +5), 29 men (age 23 +5)] engaged in sustained aerobic exercise.

Following initial screening, study subjects were given either a placebo or 250 mg of Wellmune WGP daily for 10 days.

Higher monocyte level was recorded immediately before and after exercise, as well as two hours post exercise.

Study participants also had higher levels of key cytokines (IL-2, IL-4, IL-5 and IFN gamma) following Lipopolysaccharide (LPS) stimulation when taking Wellmune WGP.

The data also showed higher levels of plasma cytokines (IL-4, IL-5, IL-7, IL-8, IL-10 and IFN gamma) two hours after exercise when the subjects had supplemented with Wellmune.

University of Houston Department of Health and Human Performance Exercise Physiology, Nutrition, and Immunology associate professor Brian McFarlin said the effect of Wellmune WGP on LPS-stimulated IL-4 and IL-5 production suggests that leukocytes were primed for higher plasma cytokines that directly mediate innate and humoral dependent immune responses.